(Q36093312)

English

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

Michael A Morse

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Amy Hobeika

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Takuya Osada

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Donna Niedzwiecki

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Paul Kelly Marcom

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kimberly L Blackwell

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Carey Anders

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Gayathri R Devi

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

H Kim Lyerly

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Timothy M Clay

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 September 2007

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

42

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

6 September 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Human dendritic cell subsets for vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

2 October 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

2 October 2017

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

2 October 2017

Dendritic cells: specialized and regulated antigen processing machines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

2 October 2017

Cross-presentation, dendritic cells, tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

2 October 2017

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

2 July 2018

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

23 September 2018

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

23 September 2018

Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

23 September 2018

Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

23 September 2018

Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2042490

23 September 2018

Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 Dendritic Cell Vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-5-42

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Dimensions Publication ID

0 references

release_46r7sz6kmrg2hp4odjgapbhuzq

1 reference

https://api.fatcat.wiki/v0/release/46r7sz6kmrg2hp4odjgapbhuzq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36093312&oldid=2198191096"